Sylentis SA, of Madrid, Spain, a subsidiary of Grupo Zeltia, presented two posters at the World Glaucoma Congress in Paris. One poster showed that topical candidate SYL040012, administered to healthy volunteers with normal intraocular pressure (IOP), demonstrated excellent local tolerance and showed a decline in IOP in most of the subjects.